853results about "Bacteriophages" patented technology

The invention provides a virulent bacteriophage and application thereof, the virulent bacteriophage is named as vBVpaPChan1 and has been preserved in China Center for Type Culture Collection on December 10, 2024, the preservation address is Wuhan University, Wuhan, Hubei, China, and the preservation number is CCTCC M 20242772. The bacteriophage is safe, environmentally friendly and free of toxic and side effects, and compared with known bacteriophages, the bacteriophage is short in incubation period, large in outbreak amount and capable of effectively killing diseases caused by vibrio parahaemolyticus chan02.

The invention discloses a virulent bacteriophage vBValSR36H with a host being vibrio alginolyticus and application of the virulent bacteriophage vBValSR36H, and relates to the technical field of microbial control. The invention provides a bacteriophage capable of efficiently cracking Vibrio alginolyticus ATCC 17749T, the bacteriophage is named as vBValSR36H, the preservation number is 66248-B1, and the preservation address is Institute of Microbiology, Academy of Sciences in Guangdong Province. The vibrio alginolyticus bacteriophage vBValSR36H provided by the invention has good environmental stability and certain bactericidal activity, and has a relatively wide environmental adaptation range and relatively long survival time. The bacteriophage vBValSR36H provided by the invention can specifically and effectively kill, prevent and control related vibrio diseases, meanwhile, virulence factor genes and drug-resistant genes are not detected in the bacteriophage, and the bacteriophage vBValSR36H has the advantages of no toxic or side effect, high safety, environmental friendliness and wide application prospect. Therefore, the vibrio alginolyticus bacteriophage vBValSR36H can be completely applied to killing and / or preventing vibrio alginolyticus for non-disease diagnosis and treatment purposes.

The invention relates to methods, uses, systems, arrays, engineered nucleotide sequences and vectors for inhibiting bacterial population growth or for altering the relative ratio of sub-populations of first and second bacteria in a mixed population of bacteria. The invention is particularly useful, for example, for treatment of microbes such as for environmental, medical, food and beverage use. The invention relates inter alia to methods of controlling microbiologically influenced corrosion (MIC) or biofouling of a substrate or fluid in an industrial or domestic system.

The invention relates to methods, uses, systems, arrays, engineered nucleotide sequences and vectors for inhibiting bacterial population growth or for altering the relative ratio of sub-populations of first and second bacteria in a mixed population of bacteria. The invention is particularly useful, for example, for treatment of microbes such as for environmental, medical, food and beverage use. The invention relates inter alia to methods of controlling microbiologically influenced corrosion (MIC) or biofouling of a substrate or fluid in an industrial or domestic system.

The technology described herein relates to methods and compositions for targeting E coli cells, such as for treating or preventing an infection by E coli cells in human or animal subjects. The method, in an embodiment, comprises administering to the subject a particle cocktail comprising a plurality of different transduction particles to E coli cells. The method, in an embodiment, comprises administering to the subject a plurality of transduction particles that encode a nuclease for targeting the genomes of B2 phylogroup E coli cells.

Strategies, systems, methods, reagents, and kits for phage-assisted continuous evolution are provided herein. These include strategies, systems, methods, reagents, and kits allowing for stringency modulation to evolve weakly active or inactive biomolecule variants, negative selection of undesired properties, and / or positive selection of desired properties.

The invention discloses a lytic bacteriophage vBVpaSR40Z and application of the lytic bacteriophage vBVpaSR40Z to prevention and control of vibrio parahaemolyticus in an aquaculture environment. The preservation number of the vibrio parahaemolyticus phage vBVpaSR40Z is as follows: GDMCC No: 67440-B1, and the vibrio parahaemolyticus phage vBVpaSR40Z is The R40Z can be used for cracking multiple strains of vibrio parahaemolyticus and vibrio alginolyticus, has the capability of adapting to an aquaculture environment, and keeps relatively high activity within the range of 4-25 DEG C and pH of 4-10; no virulence gene or drug-resistant gene is detected through genome analysis, and phylogenetic and whole genome comparison shows that the similarity between R40Z and a related phage is lower than a species level threshold value, so that R40Z is a new phage species; the R40Z can obviously inhibit the growth of a host under various infection complex numbers. The R40Z has the advantages of strong splitting capacity, good environmental stability, high genome safety, unique evolutionary characteristics and the like, and is an aquatic vibriosis biological prevention and control bacteriophage with application potential.

The invention discloses an Escherichia coli bacteriophage PEC-36 with cross-species host characteristics and application of the Escherichia coli bacteriophage PEC-36, and belongs to the technical field of biology. The Escherichia coli bacteriophage PEC-36 is separated from sewage of a pig factory, can simultaneously split O8: H7, O21: H34, O23: H16, O25: H4, O81: H27 and H25 serotype strains of Escherichia coli and fowl typhoid, London, swine cholera and other serotype strains of salmonella, and has a cross-species splitting characteristic. Experiments prove that the bacteriophage has the advantages of high titer, high stability, high safety and the like, and can remarkably inhibit the growth of escherichia coli and salmonella, so that a technical support is provided for research and development of bacteriophage preparations for treating infection related to escherichia coli and salmonella; the invention provides a safe and efficient antibiotic alternative scheme for treating human and animal Escherichia coli and salmonella related infection, and has a good application prospect.

The invention discloses a lytic bacteriophage for preventing and controlling vibrio in an aquaculture environment. The bacteriophage vBValMR42H belongs to a muscle tail bacteriophage and is insensitive to chloroform, the capsid of the bacteriophage vBValMR42H is free of lipid substances, and the preservation number is GDMCC No: 67434-B1. The bacteriophage has the characteristics of high adsorption speed, short incubation period and high cracking amount, keeps high activity in a wide range of temperature (4-55 DEG C) and pH (2-11), and has strong environmental adaptability. Genome analysis shows that the bacteriophage does not contain virulence factors, antibiotic resistance genes and lyogen related genes, and is high in biological safety. Physical development analysis shows that the method can be divided into a new genus. The bacteriophage R42H has the advantages of high splitting efficiency, good environmental stability, strong specificity, gene safety and the like, and can be used as an ideal biological prevention and control agent for preventing and controlling vibrio alginolyticus diseases in aquaculture.

A bacteriophage for specifically lysing high-virulence capsular Klebsiella pneumoniae, pertaining to the field of microorganisms. The deposit number of the Klebsiella pneumoniae bacteriophage vB_kpnP_D39 is CCTCC NO: M 2024690. In the bacteriophage liquid formulation prepared on the basis of the bacteriophage, the working titer of the bacteriophage is greater than 1 × 109 PFU / mL. The bacteriophage has high specificity and can kill all high-virulence multidrug-resistant Klebsiella pneumoniae of K1, K2, and K57 capsular serotypes, with an adsorption efficiency of 99.60%. The bacteriophage exhibits a biofilm clearance rate of 47.4%-63.2% and a capsule clearance rate of 42.1%-60.6% against the high-virulence Klebsiella pneumoniae. The bacteriophage is expected to become a safe, non-toxic agent for the prevention, control, and treatment of high-virulence multidrug-resistant Klebsiella pneumoniae infections, or an antibiotic adjuvant.

The invention relates to the technical field of bacteriophages, and provides a bacteriophage for fish nocardia and application of the bacteriophage, the bacteriophage is used for splitting fish nocardia, and the fish nocardia comes from a water body of a fish culture pond; the bacteriophage is preserved in China General Microbiological Culture Collection Center (CGMCC) on June 17, 2025, and the preservation number is CGMCC No.46495; the bacteriophage belongs to a tail bacteriophage, and the tail length is 165 + / -2nm. According to the technical scheme, the problem that at present, no bacteriophage for effectively treating and preventing fish nocardia exists is solved.

The invention discloses a high-temperature-resistant klebsiella pneumoniae phage, a composition of the high-temperature-resistant klebsiella pneumoniae phage and a kit, the high-temperature-resistant klebsiella pneumoniae phage is klebsiella pneumoniae phage P6AKPJS20, the preservation number of the high-temperature-resistant klebsiella pneumoniae phage is CCTCC (China Center For Type Culture Collection) NO: M20242965, and the high-temperature-resistant klebsiella pneumoniae phage has a nucleotide sequence as shown in SEQ ID No.1-6. The bacteriophage has broad-spectrum bactericidal ability, wide acid-base tolerance range and certain tolerance to chloroform and diethyl ether, and can still maintain high activity while splitting target bacteria; meanwhile, the bacteriophage has good tolerance to high temperature and can adapt to various application conditions in production.

The invention relates to methods, uses, systems, arrays, engineered nucleotide sequences and vectors for inhibiting bacterial population growth or for altering the relative ratio of sub-populations of first and second bacteria in a mixed population of bacteria. The invention is particularly useful, for example, for treatment of microbes such as for environmental, medical, food and beverage use. The invention relates inter alia to methods of controlling microbiologically influenced corrosion (MIC) or biofouling of a substrate or fluid in an industrial or domestic system.

The invention provides systems, methods, reagents, apparatuses, vectors, and host cells for the continuous evolution of nucleic acids. For example, a lagoon is provided in which a population of viral vectors comprising a gene of interest replicates in a stream of host cells, wherein the viral vectors lack a gene encoding a protein required for the generation of infectious viral particles, and wherein that gene is expressed in the host cells under the control of a conditional promoter, the activity of which depends on a function of the gene of interest to be evolved. Some aspects of this invention provide evolved products obtained from continuous evolution procedures described herein. Kits containing materials for continuous evolution are also provided.

The invention discloses a klebsiella pneumoniae bacteriophage vBKpnPGZMUVR2301 and application thereof, and relates to the technical field of biology. The klebsiella pneumoniae bacteriophage vBKpnPGZMUVR2301 is preserved in Guangdong Microbial Culture Collection Center on October 14, 2024, the preservation address is the 5th floor of the building 59, No.100 Courtyard, Xianlie Middle Road, Guangzhou, and the preservation number is GDMCC No: 65268-B1. The bacteriophage keeps stable titer in a wide pH range (4-10) and a temperature interval (4-50 DEG C), and the highest titer can reach more than 109 pfu / mL. The bacteriophage can efficiently split klebsiella pneumoniae. The invention provides powerful technical support for developing novel antibacterial drugs and treatment schemes for klebsiella pneumoniae, and shows wide application prospect and potential clinical value.

The invention relates to the field of aquaculture, and particularly discloses a high-splitting-property aeromonas caviridis bacteriophage and application of the high-splitting-property aeromonas caviridis bacteriophage. The invention relates to a high-cracking aeromonas caviridis phage, which has a preservation name of RKP-AE24001, is preserved in No.3, No.1 yard, Beichen West Road, Chaoyang District, Beijing on June 14, 2024, and has a preservation number of CGMCC (China General Microbiological Culture Collection Center) No.45944. According to the invention, a strain of aeromonas cainea is separated, the strain of aeromonas cainea bacteriophage is separated by taking the strain as a host, and the aeromonas cainea bacteriophage has a strong splitting effect on the aeromonas cainea separated in a culture environment.

The present invention concerns engineered phagemids and methods for antibacterial peptide delivery against bacterial pathogens, in particular Clostridioides difficile.

The present invention relates to the technical field of phages. Provided are a KL2-type Acinetobacter baumannii phage and a screening method therefor, a phage composition and the use, and a drug. The KL2-type Acinetobacter baumannii phage is named AB_SZL2, and is deposited in the China Center for Type Culture Collection with the deposit number CCTCC NO: M20241522; or the KL2-type Acinetobacter baumannii phage is named AB_SZL3, and is deposited in the China Center for Type Culture Collection with the deposit number CCTCC NO: M20241523. The KL2-type Acinetobacter baumannii phage can accurately target KL2-type Acinetobacter baumannii, and has an efficient bactericidal effect, thereby reducing the harm of KL2-type Acinetobacter baumannii and effectively addressing the problem of the antibiotic resistance of KL2-type Acinetobacter baumannii.

The invention discloses application of a method for enhancing the treatment effect of salmonella bacteriophage, and relates to the technical field of microorganisms. According to the method, bacteriophage is added into salmonella for in-vitro culture, after continuous subculture, the salmonella is dropwise added to an SS plate containing the bacteriophage, and resistant bacteria of the bacteriophage are screened. The split bacteriophage is screened aiming at the resistant bacteria of the bacteriophage, and the split bacteriophage and the initial bacteriophage form a bacteriophage cocktail formula, so that the salmonellosis can be well prevented and treated, and the generation of the resistant bacteria is delayed. The method has the beneficial effects that compared with the existing method for screening the bacteriophage-resistant bacteria through a double-layer plate method, the method is more convenient, the operation is simple, and the screening efficiency of the bacteriophage-resistant bacteria is greatly improved. The bacteriophage cocktail contains the bacteriophage for cracking the resistant bacteria, so that the treatment effect of the bacteriophage is improved, and the practical application scene is quite high.

The invention discloses a composite antibacterial preparation containing antibacterial peptide and traditional Chinese medicines as well as a preparation method and application of the composite antibacterial preparation, and belongs to the technical field of biological medicines. The antibacterial peptide provided by the invention is a transmembrane protein derived from bacteriophage, and the core function of the antibacterial peptide is that bacterial cell lysis is promoted by destroying a connection structure of a peptidoglycan layer and lipoprotein of a bacterial cell wall, so that an antibacterial effect is achieved. The amino acid sequence of the antibacterial peptide is shown as SEQ ID NO: 3, the antibacterial peptide is combined with traditional Chinese medicines to form a composite antibacterial preparation, and experiments prove that the composite antibacterial preparation has a relatively good antibacterial effect on gram-positive bacteria and gram-negative bacteria and can be applied to the medical field, such as surgical instrument disinfection and drug-resistant bacterial infection treatment; the field of daily chemicals, such as antibacterial hand sanitizers and wound dressings; in the field of agriculture, for example, animal feed additives for preventing and treating intestinal infection have a good market application prospect.

Compositions, methods and systems for targeted delivery using one or more shuttles operably linked to one or more cargos (e.g., cargo polypeptides, e.g., cargo oligonucleotides) and subsequent quantification of an abundance of one or more cargos (e.g, proteins) in a mixture (e.g., a complex mixture (e.g., in vivo)) or in a specific cell, tissue, or organ of interest (e.g., in vivo) using barcodes (e.g., peptide barcodes), binders (e.g., polypeptide binders), and binding agents (e.g., phage) are provided herein.

The invention belongs to the technical field of microbial antibacterial preparations, and particularly discloses a novel strong vibrio parahaemolyticus bacteriophage isolated strain vBVpSCC6 and application of the novel strong vibrio parahaemolyticus bacteriophage isolated strain vBVpSCC6. The bacteriophage vBVpSCC6 is preserved in the Guangdong Microbial Culture Collection Center on September 14, 2020, and the preservation number is GDMCC (China General Microbiological Culture Collection Center) NO: 61189-B1. The bacteriophage has good tolerance to environments such as temperature, pH, ultraviolet rays and the like, and has a good prevention and control effect on aquatic product pollution caused by vibrio parahaemolyticus. The bacteriophage has a lysis effect on multi-drug-resistant vibrio parahaemolyticus, can replace antibiotics to play a bacteriostatic role, effectively solves the problem of drug resistance faced by current antibiotic treatment, and has relatively good utilization value and application prospect. The bacteriophage can also be prepared into a composition with other bacteriophages to play a synergistic effect, and the bacteriophage can be applied to wider-spectrum antibacterial or bacteriostatic application.

Bacteriophages that comprise a tail fiber protein sequence comprising a C terminus host recognition site described by SEQ ID NO: 1 and which infect Ralstonia solanacearum which causes bacterial wilt disease are disclosed. Compositions comprising these bacteriophages may be employed as wilt control agents. Methods for preventing or treating diseases caused by Ralstonia solanacearum such as bacterial wilt disease are also disclosed. A bacterial wilt disease control method in a plant may include administering such bacteriophages to a plant or to a plant growth medium and can be effective against a wide variety of Ralstonia solanacearum strains. Nucleic acids encoding the C terminus host recognition site and amino acid sequences comprising the host recognition site are also disclosed.

Described herein are methods of inserting nucleic acid sequences into host cells. Also described herein are genetically stable host cells comprising inserted nucleic acid sequences and methods of using such host cells in the generation of proteins.

The invention belongs to the technical field of microorganisms, and discloses a bacteriophage which comprises a bacteriophage strain M01 with the preservation number of CCTCC M 20251724 or a variant strain of the bacteriophage strain M01. The variant strain and the bacteriophage strain M01 at least have 95% of average nucleotide identity on the genome. The bacteriophage M01 or the variant strain thereof provided by the invention has strong adsorption and lysis effects on aeromonas hydrophila, does not have genes for coding toxin, virulence factor or antibiotic resistance in a genome, and has good temperature stability and acid-base tolerance; the aeromonas hydrophila can be well applied to aquaculture to prevent and / or treat bacterial septicemia and other diseases caused by aeromonas hydrophila infection.

The application belongs to the field of medicine, and particularly relates to a cell penetrating peptide Phage-Dec and application thereof in antibiosis. The cell penetrating peptide Phage-Dec has excellent cell penetration ability and antibacterial activity, can effectively penetrate the cell membrane, target and inhibit bacterial growth, and thus achieves the purpose of antibiosis. Research shows that Phage-Dec has a significant inhibitory effect on various pathogenic bacteria, and can effectively reduce the reproduction speed of bacteria. The use of the cell penetrating peptide provides a new idea for antibacterial treatment, has a good clinical application prospect, and lays a solid foundation for developing a new antibacterial drug based on a bacteriophage source.

The invention belongs to the field of prevention and control of bacterial diseases of aquatic animals, and discloses an acid-resistant broad-spectrum vibrio parahaemolyticus bacteriophage LVPP58 and application of the acid-resistant broad-spectrum vibrio parahaemolyticus bacteriophage LVPP58 in vibrio disease prevention and control, and the preservation number of the bacteriophage is CCTCC M 2025322. The bacteriophage is a broad-spectrum vibrio parahaemolyticus bacteriophage, not only can split vibrio parahaemolyticus, but also can split vibrio alginolyticus, the bacteriophage LVPP58 is stable in titer at the pH of 3-11 and the temperature of 30-60 DEG C, the bacteriophage and antibiotics are combined for use, a synergistic effect can be generated, the treatment effect is enhanced, the occurrence rate of drug resistance is reduced, and a new strategy is provided for solving the problem of bacterial drug resistance.

The invention discloses identification and application of a mycobacterium tuberculosis bacteriophage susceptibility gene, and a gene target which affects mycobacterium bacteriophage infection efficiency is obtained through combined application of a mycobacterium tuberculosis CRISPR-KO library and a CRISPRi library and bacteriophage D29 infection screening. Reagents or drugs targeting phage susceptibility genes or encoded proteins thereof are screened based on the gene targets, and the reagents or drugs can knock out the phage susceptibility genes or inhibit expression of the phage susceptibility genes, or inhibit activity of the encoded proteins of the phage susceptibility genes, serve as phage synergists, or are combined with antibiotics to be used with phages, and can be used for preparing drugs for treating the phage susceptibility genes or the encoded proteins of the phage susceptibility genes. The bacteriophage-antibiotic composition has the advantages that a synergistic sterilization effect is achieved, a new strategy is provided for bacteriophage-antibiotic combined treatment of drug-resistant mycobacterium infection, rapid sterilization is expected to be achieved, the treatment course is shortened, and finally the target of rapid treatment of tuberculosis and other pathogenic mycobacterium infection is achieved.

The present disclosure provides for a combination of bacteriophages from various environmental sources combined to produce a phage mixture targeting shiga-toxin-producing Escherichia coli strains. Techniques and methods of production and use of the phage combinations are also provided.

The invention discloses a mycobacteriophage and application thereof, and relates to the technical field of bacteriophages. The mycobacteriophage is named as Mycobacter phage BZNK001, is preserved in Guangdong Microbial Culture Collection Center, has a preservation number of GDMCC No: 67907-B1, does not contain antibiotic drug-resistant genes and integrase genes, has excellent biological safety and good environmental tolerance, can maintain high biological activity in a temperature range of 37-50 DEG C under an acid-base condition of pH 5-9, and can be used for preparing the antibiotic drug-resistant gene and integrase gene-containing mycobacteriophage for preventing and treating the antibiotic drug-resistant gene and integrase gene-containing mycobacteriophage for preventing and treating the antibiotic drug-resistant gene and integrase gene-containing mycobacteriophage. The bacillus subtilis has broad-spectrum and high-efficiency non-tuberculous mycobacterium cracking activity, and can effectively crack four clinical key mycobacteria such as mycobacterium abscessus, mycobacterium avium, mycobacterium intracellularis and mycobacterium smegmatis. According to the invention, a mycobacteriophage resource library is enriched, a novel and stable biological prevention and control means is provided for efficient prevention and control of mycobacteria, and the mycobacteriophage has good clinical application and industrialization values.